LINC01001 Promotes Progression of Crizotinib-Resistant NSCLC by Modulating IGF2BP2/MYC Axis

Overview of attention for article published in Frontiers in Pharmacology, September 2021

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (74th percentile)

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 8,518 followers.

LINC01001 Promotes Progression of Crizotinib-Resistant NSCLC by Modulating IGF2BP2/MYC Axis #lymphoma #lymsm https://t.co/aytwgCLMH4

RT @FrontPharmacol: New Research: LINC01001 Promotes Progression of Crizotinib-Resistant NSCLC by Modulating IGF2BP2/MYC Axis https://t.co/…

New Research: LINC01001 Promotes Progression of Crizotinib-Resistant NSCLC by Modulating IGF2BP2/MYC Axis https://t.co/PwKkHCsWzX #pharmacology

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.